These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 27167196)

  • 1. Coexistence of YWHAZ amplification predicts better prognosis in muscle-invasive bladder cancer with CDKN2A or TP53 loss.
    Liu S; Wu Y; Yang T; Feng C; Jiang H
    Oncotarget; 2016 Jun; 7(23):34752-8. PubMed ID: 27167196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.
    Rebouissou S; Hérault A; Letouzé E; Neuzillet Y; Laplanche A; Ofualuka K; Maillé P; Leroy K; Riou A; Lepage ML; Vordos D; de la Taille A; Denoux Y; Sibony M; Guyon F; Lebret T; Benhamou S; Allory Y; Radvanyi F
    J Pathol; 2012 Jul; 227(3):315-24. PubMed ID: 22422578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockdown of tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta (YWHAZ) enhances tumorigenesis both in vivo and in vitro in bladder cancer.
    Liu S; Jiang H; Wen H; Ding Q; Feng C
    Oncol Rep; 2018 May; 39(5):2127-2135. PubMed ID: 29512774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The
    Han M; Yamaguchi S; Onishi M; Fujii T; Hosoya M; Wen X; Kido H; Kato S
    Anticancer Res; 2022 May; 42(5):2277-2288. PubMed ID: 35489754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A TP53-Associated Immune Prognostic Signature for the Prediction of Overall Survival and Therapeutic Responses in Muscle-Invasive Bladder Cancer.
    Wu X; Lv D; Cai C; Zhao Z; Wang M; Chen W; Liu Y
    Front Immunol; 2020; 11():590618. PubMed ID: 33391264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TP53 and CDKN2a mutations in never-smoker oral tongue squamous cell carcinoma.
    Heaton CM; Durr ML; Tetsu O; van Zante A; Wang SJ
    Laryngoscope; 2014 Jul; 124(7):E267-73. PubMed ID: 24431303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer.
    Qureshi KN; Griffiths TR; Robinson MC; Marsh C; Roberts JT; Hall RR; Lunec J; Neal DE
    Clin Cancer Res; 1999 Nov; 5(11):3500-7. PubMed ID: 10589764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer.
    Ecke TH; Lenk SV; Schlechte HH; Loening SA
    Anticancer Res; 2003; 23(2A):957-62. PubMed ID: 12820330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. YWHAZ amplification/overexpression defines aggressive bladder cancer and contributes to chemo-/radio-resistance by suppressing caspase-mediated apoptosis.
    Yu CC; Li CF; Chen IH; Lai MT; Lin ZJ; Korla PK; Chai CY; Ko G; Chen CM; Hwang T; Lee SC; Sheu JJ
    J Pathol; 2019 Aug; 248(4):476-487. PubMed ID: 30945298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of homozygous deletions and multiple duplications at the CDKN2A (p16INK4a)/ARF (p14ARF) locus in urinary bladder cancer.
    Berggren de Verdier PJ; Kumar R; Adolfsson J; Larsson P; Norming U; Onelöv E; Wijkström H; Steineck G; Hemminki K
    Scand J Urol Nephrol; 2006; 40(5):363-9. PubMed ID: 17060081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group.
    Lerman DM; Monument MJ; McIlvaine E; Liu XQ; Huang D; Monovich L; Beeler N; Gorlick RG; Marina NM; Womer RB; Bridge JA; Krailo MD; Randall RL; Lessnick SL;
    Pediatr Blood Cancer; 2015 May; 62(5):759-65. PubMed ID: 25464386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer.
    Bellmunt J; Kim J; Reardon B; Perera-Bel J; Orsola A; Rodriguez-Vida A; Wankowicz SA; Bowden M; Barletta JA; Morote J; de Torres I; Juanpere N; Lloreta-Trull J; Hernandez S; Mouw KW; Taplin ME; Cejas P; Long HW; Van Allen EM; Getz G; Kwiatkowski DJ
    Cancer Res; 2020 Oct; 80(20):4476-4486. PubMed ID: 32868381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer.
    Markl ID; Jones PA
    Cancer Res; 1998 Dec; 58(23):5348-53. PubMed ID: 9850064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
    Eltze E; Wild PJ; Wülfing C; Zwarthoff EC; Burger M; Stoehr R; Korsching E; Hartmann A
    Eur Urol; 2009 Nov; 56(5):837-45. PubMed ID: 18945538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical course of bladder neoplasms and single nucleotide polymorphisms in the CDKN2A gene.
    Sakano S; Berggren P; Kumar R; Steineck G; Adolfsson J; Onelöv E; Hemminki K; Larsson P
    Int J Cancer; 2003 Mar; 104(1):98-103. PubMed ID: 12532425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allelic deletions of cell growth regulators during progression of bladder cancer.
    Primdahl H; von der Maase H; Christensen M; Wolf H; Orntoft TF
    Cancer Res; 2000 Dec; 60(23):6623-9. PubMed ID: 11118045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A.
    Elnenaei MO; Gruszka-Westwood AM; A'Hernt R; Matutes E; Sirohi B; Powles R; Catovsky D
    Haematologica; 2003 May; 88(5):529-37. PubMed ID: 12745272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Body mass index (BMI) and mutations of tumor suppressor gene p53 (TP53) in patients with urinary bladder cancer.
    Ecke TH; Schlechte HH; Gunia S; Lenk SV; Loening SA
    Urol Oncol; 2008; 26(5):470-3. PubMed ID: 18367114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TP53 and CDKN2A mutations in patients with early-stage lung squamous cell carcinoma: an analysis of the correlations and prognostic outcomes.
    Wang P; Wang F; He H; Chen Y; Lin H; Chen P; Chen X; Liu S
    Ann Transl Med; 2021 Aug; 9(16):1330. PubMed ID: 34532467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detecting homozygous deletions in the CDKN2A(p16(INK4a))/ARF(p14(ARF)) gene in urinary bladder cancer using real-time quantitative PCR.
    Berggren P; Kumar R; Sakano S; Hemminki L; Wada T; Steineck G; Adolfsson J; Larsson P; Norming U; Wijkström H; Hemminki K
    Clin Cancer Res; 2003 Jan; 9(1):235-42. PubMed ID: 12538475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.